How much funding has Comanche Biopharma raised?

Comanche Biopharma has raised $115.0M in total funding, most recently a Series C round.

Who are Comanche Biopharma's investors?

Comanche Biopharma's investors include Atlas Venture, New Enterprise Associates, GV, F-Prime Capital, Lilly Asia Ventures, Broadview Ventures.

When was Comanche Biopharma founded?

Comanche Biopharma was founded in 2020.

Where is Comanche Biopharma headquartered?

Comanche Biopharma is headquartered in Concord, Massachusetts, United States.

What industry is Comanche Biopharma in?

Comanche Biopharma operates in Biotech, Healthcare.

How many employees does Comanche Biopharma have?

Comanche Biopharma has 11-50 employees.

Comanche Biopharma

formerly Comanche

Making every pregnancy around the world safer

Concord, United States · Founded 2020 · $115.0M raised

Biotech

Healthcare

Headquarters: Concord, Massachusetts
Employees: 11–50
Founded: 2020
Business Model: B2B

Website: comanchebiopharma.com
Total Funding: $115.0M
Last Round: $40.0M Series CJan 2026
Rounds: 3

About

Comanche Biopharma is a clinical-stage biopharmaceutical company developing CBP-4888, an investigational siRNA medicine for preterm preeclampsia. Founded in 2020 and headquartered in Concord, MA, Comanche's mission is to develop and make globally available the first therapy targeting a root cause of preeclampsia — a life-threatening pregnancy complication affecting millions of women worldwide. The EMA granted Orphan Drug Designation for CBP-4888 in 2025.

Summary

Comanche Biopharma is a Biotech company based in Concord, United States, founded in 2020. It has raised $115.0M in total across 3 rounds, most recently a $40.0M Series C round in Jan 2026. Investors include Atlas Venture, New Enterprise Associates and GV.